Choose Language

"Dedicated to giving our patients a promise for tomorrow"

POTENT-C

Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer in Potent Men: A Prospective, Phase II Trial

This study is a clinical trial to determine and assess the change in the rate of potency in men with low-risk, localized, unilateral prostate cancer who have not received previous treatment.  A total of 86 men between 40 to 69 years of age with biopsy proven, early stage localized prostate cancer will receive unilateral nerve-sparing cryoablation.  The study includes a screening/pre-operative visit, a cryoablation procedure day, and 10 follow up visits with completion of validated questionnaires over the course of 36 months.  The first follow-up visit will occur within 2 weeks (±1 week) after cryoablation.  Thereafter, follow-up visits will be scheduled, from the date of procedure, every 3 months (±3 weeks) for 18 months and every 6 months (±3 weeks) thereafter until the patient completes the protocol, 36 months after the cryoablation procedure. Cryoablation is an FDA-approved and accepted treatment for prostate cancer.  The potential benefits of this study include better preservation of potency, continence and health related quality of life compared to other treatment options.

Long Island Web Design